The tradeoff between some dilution vs. losing most of the revenue to the partner was probably the right one this time.
(Of course when I invested initially I hoped for quick partnering and profit. That did not happen, But the risk/reward prospect is a heck of lot better now.)
I believe you are completely wrong. The company raised the money to lift the lid on the stock which is caused by people not buying the stock because they started the phase 3 without having the money to finish it. The next question was people saying that since they didn't have the money to finish the trial that the pharma partners would play hardball.
In my opinion the company will partner the drug to de risk the process. If they spend all of their money to finish the phase 3 and it fails even though the phase 2 worked the stock price will get killed and they wouldn't have the money for 4232.
The will partner mc-1 and I believe they will get an upfront payment of 25- 50 million for it and the partner will pay for the trials. they will also be able to get some kind of co promote deal using their existing salse force.
This will also allow them to start their phase 3 trials in 4232 which is probably a bigger market.
News 
Market Data 
Discover 
AI
